Intellia Therapeutics Inc
NTLA
Market Cap$915.09M
Close$
$-5.18
162.6% downside
Current Fair Value
162.6% downsideOvervalued by 162.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $915.09 Million |
|---|---|
| Enterprise Value | $956.77 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.25 |
| Beta | 2.23 |
| Outstanding Shares | 101,855,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.73 |
|---|---|
| PEG | -15.72 |
| Price to Sales | - |
| Price to Book Ratio | 1.04 |
| Enterprise Value to Revenue | 22.21 |
| Enterprise Value to EBIT | -1.81 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...